RxDoctor Payments Data

Sangita Sahay, MD

Internal Medicine · Melbourne, FLNPI 1609860626

Payments from drug & device makers

$1,255in general payments, 2019–2025

Across 70 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$271
  • Novo Nordisk$247
  • AstraZeneca$227
  • GSK$116
  • Paratek Pharmaceuticals, Inc.$92
  • Boehringer Ingelheim$87
  • plus $214 from 8 others

What the payments were for

  • Food & beverage$1,255100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,255 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$363,892
Medicare patients
690
Services billed
4,777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$85,690
JardianceEmpagliflozin22$25,649
EliquisApixaban13$22,528
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,814
Spiriva RespimatTiotropium Bromide17$8,890
SymbicortBudesonide/Formoterol Fumarate16$4,525
Fluticasone Propionate HfaFluticasone Propionate17$4,424
ValacyclovirValacyclovir Hcl27$3,435
Rosuvastatin Calcium193$3,418
Albuterol Sulfate HfaAlbuterol Sulfate111$3,041
Labetalol Hcl67$2,747
SynthroidLevothyroxine Sodium33$2,491
Theophylline ErTheophylline Anhydrous20$2,382
Valsartan56$2,242
Lisinopril236$2,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$247$85,69065 claims
Boehringer IngelheimJardiance, Spiriva Respimat$87$34,53939 claims
GSKTrelegy Ellipta$116$12,81414 claims
AstraZenecaSymbicort$227$4,52516 claims
AbbVieSynthroid$61$2,49133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →